ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).

Authors: Jain, Rohit K., Ong, Faustine, Faltas, Bishoy Morris, Tagawa, Scott T., Jiang, Di Maria, Heiligh, Jazlyn, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Pelosof, Lorraine Cheryl, Yang, Yuanquan, Graham, Laura, Arafat, Waddah, Synold, Timothy Walter, Chatwal, Monica Sheila, Zhang, Jingsong, Chadha, Jus, Sonpavde, Guru P.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p808-808, 242p

Predicting clinical outcomes in the S1314-COXEN trial using a multimodal deep learning model integrating histopathology, cell types, and gene expression.

Authors: Faltas, Bishoy Morris, Bai, Zilong, Osman, Mohamed, Brendel, Matthew, Tangen, Catherine, Flaig, Thomas W., Thompson, Ian M., Plets, Melissa, Lucia, M. Scott, Theodorescu, Dan, Gustafson, Daniel, Daneshmand, Siamak, Meeks, Joshua J, Choi, Woonyoung, Dinney, Colin P.N., Elemento, Olivier, Lerner, Seth P., McConkey, David James, Wang, Fei

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p533-533, 193p

Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.

Authors: Shohdy, Kyrillus Samaan, Villamar, Dario Martin, Cao, Yen, Trieu, Janson, Price, Kristin Sedgwick, Nagy, Rebecca, Tagawa, Scott T., Molina, Ana M., Sternberg, Cora N., Nanus, David M., Grivas, Petros, Sonpavde, Guru P., Mosquera, Juan Miguel, Elemento, Olivier, Vogelzang, Nicholas J., Faltas, Bishoy Morris

Source: Journal of clinical oncology. 40(6 suppl):532-532

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155645489.0x000001&indx=1&recIds=ETOCvdc_100155645489.0x000001

Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.

Authors: Nauseef, Jones T., Singh, Sharon, Tan, Angela, Patel, Amie, Robinson, Brian D., Khani, Francesca, Drake, Charles G., Lim, Emerson A., Stein, Mark N., Heath, Elisabeth I., Beltran, Himisha, Molina, Ana M., Faltas, Bishoy Morris, Ballman, Karla V., Sternberg, Cora N., Tagawa, Scott T., Nanus, David M.

Source: Journal of clinical oncology. 39(15 suppl):TPS5095-TPS5095

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173205340.0x000001&indx=1&recIds=ETOCvdc_100173205340.0x000001

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.

Authors: Shohdy, Kyrillus S., Villamar, Dario M., Cao, Yen, Trieu, Janson, Price, Kristin S., Nagy, Rebecca, Tagawa, Scott T., Molina, Ana M., Sternberg, Cora N., Nanus, David M., Mosquera, Juan Miguel, Elemento, Olivier, Sonpavde, Guru P., Grivas, Petros, Vogelzang, Nicholas J., Faltas, Bishoy Morris

Source: British Journal of Cancer; Feb2022, Vol. 126 Issue 3, p430-439, 10p

Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).

Authors: Grivas, Petros, Daneshmand, Siamak, Makarov, Vladimir, Bellmunt, Joaquim, Sridhar, Srikala S., Sonpavde, Guru P., Cole, Suzanne, Tripathi, Abhishek, Faltas, Bishoy Morris, Lerner, Seth P., Fleming, Mark T., Loriot, Yohann, Meeks, Joshua J, Master, Viraj A., Davis, Kimberlee, Van Veenhuyzen, David Friedrich, Afifi, Shugufa, Pal, Sumanta Kumar, Gupta, Shilpa

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4511-4511, 1p

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Authors: Nagar, Himanshu, Ballman, Karla V., Tagawa, Scott T., Tan, Alan, Faltas, Bishoy Morris, Sheybani, Arshin, Baghaie, Shiva, Schwartz, Lawrence Howard, Kozono, David E., Bogart, Jeffrey A, Conway, Olivia, Mazza, Gina L., Chen, Ronald C., Laccetti, Andrew Leonard, Rosenberg, Jonathan E., Morris, Michael J.

Source: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, pTPS589-TPS589, 1p